SLS
SELLAS Life Sciences Group, Inc · Healthcare · Biotechnology
$10.38
-14.71% today · -14.50% 1W
Oct 28 close or latest
After hours $10.36 -0.15% ·
ReadoutWhy it movedthe Oct 28 session
Down on Phase 3 leukemia trial milestone
- SLS −14.71% on the last session vs SPY +0.34%: −15.1 pts of stock-specific move.
- News: Sellas shares fell 18% after Phase 3 REGAL trial reached the 80th death triggering final analysis, per tikr.com. (tikr.com)
- Aftermath, mention spike (trendy) (42 mentions vs 2.7/day the week before): After its 6 mention spikes in the past 5 years, SLS was higher a day later 4 times out of 6; half the outcomes fell between -1.0% and +15.0%. History, not a forecast.
- 45 Reddit mentions in the past 24 hours, 72% positive over the week · today's pace is 15.5× its recent daily average.
- Market backdrop (Today): Federal Reserve issues FOMC statement; S&P futures -0.04%, 10-year yield +1bp in the 30 minutes after.
- Activity: volume 4.1× its 20-day average.
Assembled from Wallsti's own signals and the session's headlines and filings read by AI (Claude); it can misread, so the sources are linked.
Since the closemarket closed · opens
- After hours: $10.36, -0.15% vs the Oct 28 close, last trade .
- Index futures: Dow -0.13%, S&P -0.38%, Nasdaq -0.92%, Russell +0.03%.
Shown while the market is closed. Prices outside regular hours trade thinly and often change at the open (Yahoo Finance, delayed).
Activity & positioning
- Volume
- 4.1× its 20-day average
- Short interest
- 26.7% of float · -9% vs prior report · 10.3 days to cover as of Oct 15
- Options volume
- 18,016 calls · 6,668 puts (put/call 0.37)Oct 28; averages after 10 sessions
- Implied volatility
- 127% at the money, Nov 6 expiry
- Options-implied move
- ±35.2% through the Nov 11 earnings
Moved with
Biotech ETF (XBI) +1.7% +1.4 pts vs SPY
Headlines
- Sellas’ GPS Trial Records 80th Event — Retail Says ‘Completely Irrational Sell Off’ As SLS Stock Tanks 18%
- Sellas Sinks 18% as Phase 3 Leukemia Trial Reaches “Critical Milestone” Ahead of Final Data
- SELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia
- SLS Stock Gets A BlackRock Spotlight Ahead Of Phase 3 AML Data — Bulls Spot 2027 European GPS Approval Forecast
- SLS Stock Jumps Overnight: Retail Eyes Huge Potential Buyout As CEO Marks 15 Years
- SLS Stock Climbs Pre-Market: CEO's Early Anniversary Post Has Retail Bulls Buzzing About Major News
- SLS Stock Logs Worst Week In Over A Month: Retail Bulls Bet ASH Embargo Is Keeping Regal Results Under Wraps
- SLS, IBRX Rise Premarket: Funds Raise Their Bets As J&J Stays ‘On The Lookout’ For Deals
- SLS Stock Jumps Overnight: Retail Sees Big Pharma Buyout Clues In 'M&A Negotiation Lounge' Booth At ASH
- SLS Stock’s 2-Week Rally Loses Steam: Retail Sees ‘Peanut Prices’ As Fresh AML Study Fuels Regal Hopes
Fetched hourly from Yahoo Finance (the stock) and Google News (its themes). ✦ marks the headline an AI-read catalyst cited.
Key facts
- Market cap
- $2.1B
- Held by institutions
- 37.1%
- 52-week range
- 1.39–15.88
- Analyst mean target
- $32.50
- Next earnings
- Nov 11 est.
- Forward P/E
- -103.2
Recent events
News (AI read) ▼
Sellas shares fell 18% after Phase 3 REGAL trial reached the 80th death triggering final analysis, per tikr.com. · tikr.comSEC filing
8-K: results (item 2.02) · filingEarnings ▼
2Q2026 results: EPS −$0.05 vs −$0.04 expected miss −$0.01; next session +6.5% (+6.3 vs SPY)SEC filing
8-K: results, other event (item 2.02, 8.01) · filingSEC filing
8-K: executive or director change (item 5.02) · filingSEC filing
8-K: other event (item 8.01) · filingSEC filing
8-K: results (item 2.02) · filingSEC filing
S-3ASR: automatic shelf registration · filingSEC filing
8-K: results (item 2.02) · filingEarnings ▲
4Q2025 results: EPS −$0.05 vs −$0.06 expected beat +$0.01; next session -8.5% (-7.0 vs SPY)Analyst ▲
Maxim Group maintained Buy, raised target $7.00 → $10.00SEC filing
8-K: other event (item 8.01) · filing